JP2006515829A - 炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用 - Google Patents

炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用 Download PDF

Info

Publication number
JP2006515829A
JP2006515829A JP2003583427A JP2003583427A JP2006515829A JP 2006515829 A JP2006515829 A JP 2006515829A JP 2003583427 A JP2003583427 A JP 2003583427A JP 2003583427 A JP2003583427 A JP 2003583427A JP 2006515829 A JP2006515829 A JP 2006515829A
Authority
JP
Japan
Prior art keywords
carboxylic acid
piperidine
aryl
alkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003583427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515829A5 (enExample
Inventor
ジョエル・エム・リンデン
ゲイル・ダブリュー・サリバン
ティモシー・エル・マクドナルド
ダブリュー・マイケル・シェルド
トム・ジー・オブリグ
ジェイソン・エム・リーガー
Original Assignee
ユニバーシティ オブ バージニア パテント ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29254444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006515829(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユニバーシティ オブ バージニア パテント ファウンデーション filed Critical ユニバーシティ オブ バージニア パテント ファウンデーション
Publication of JP2006515829A publication Critical patent/JP2006515829A/ja
Publication of JP2006515829A5 publication Critical patent/JP2006515829A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2003583427A 2002-04-10 2003-04-10 炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用 Pending JP2006515829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37143402P 2002-04-10 2002-04-10
US38718402P 2002-06-07 2002-06-07
PCT/US2003/011146 WO2003086408A1 (en) 2002-04-10 2003-04-10 Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2006515829A true JP2006515829A (ja) 2006-06-08
JP2006515829A5 JP2006515829A5 (enExample) 2006-07-20

Family

ID=29254444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003583427A Pending JP2006515829A (ja) 2002-04-10 2003-04-10 炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用

Country Status (7)

Country Link
US (1) US20090170803A1 (enExample)
EP (1) EP1496911B1 (enExample)
JP (1) JP2006515829A (enExample)
AT (1) ATE381336T1 (enExample)
AU (1) AU2003234716A1 (enExample)
DE (1) DE60318192T2 (enExample)
WO (1) WO2003086408A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507907A (ja) * 2007-12-20 2011-03-10 ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー Ａ２ａｒアゴニストとしての置換４−｛３−［６−アミノ−９−（３，４−ジヒドロキシ−テトラヒドロ−フラン−２−イル）−９ｈ−プリン−２−イル］−プロプ−２−イニル｝−ピペリジン−１−カルボン酸エステル
JP2011526894A (ja) * 2008-07-03 2011-10-20 ユニバーシティ オブ バージニア パテント ファウンデーション アパデノソンの単位投薬量

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
EP1434782A2 (en) * 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1746885A4 (en) * 2004-05-03 2010-09-08 Univ Virginia AGONISTS OF A2A ADENOSINE RECEPTORS FOR THE TREATMENT OF NEEDLE INJURY IN DIABETES
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7605143B2 (en) * 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
EP2021350B1 (en) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
CA2766937A1 (en) 2009-07-09 2011-01-13 Cbt Development Limited Combined preparation for use as a medicament
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
US9085560B2 (en) 2009-08-17 2015-07-21 Intellikine, Inc. Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US5593973A (en) * 1987-09-04 1997-01-14 Hemispherx Biopharma Inc. Treatment of viral hepatitis with mismatched dsRNA
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
CA2151741C (en) * 1991-12-30 2001-12-11 Alan Justice Methods of producing analgesia and enhancing opiate analgesia
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
EP1044004A1 (en) * 1998-01-08 2000-10-18 The University Of Virginia Patent Foundation A2a adenosine receptor agonists in combination with a type iv phosphodiesterase inhibitors
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
BR9914526A (pt) * 1998-10-16 2001-07-03 Pfizer Derivados de adenina
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
WO2000072799A2 (en) * 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
AU2001278708A1 (en) * 2000-09-08 2002-03-22 Toa Eiyo Ltd. Adenosine derivatives and use thereof
GB0022695D0 (en) * 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
BRPI0211932B1 (pt) * 2001-08-17 2016-12-06 Novartis Ag composição farmacêutica na forma de dosagem sólida para liberação oral, e uso de sal dissódio de ácido n-(5-cloro-saliciloil)-8-aminocaprílico (5-cnac)
EP1434782A2 (en) * 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
EP1746885A4 (en) * 2004-05-03 2010-09-08 Univ Virginia AGONISTS OF A2A ADENOSINE RECEPTORS FOR THE TREATMENT OF NEEDLE INJURY IN DIABETES
US7605143B2 (en) * 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2007092936A2 (en) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Method to treat gastric lesions
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008124150A1 (en) * 2007-04-09 2008-10-16 University Of Virginia Patent Foundation Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) * 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507907A (ja) * 2007-12-20 2011-03-10 ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー Ａ２ａｒアゴニストとしての置換４−｛３−［６−アミノ−９−（３，４−ジヒドロキシ−テトラヒドロ−フラン−２−イル）−９ｈ−プリン−２−イル］−プロプ−２−イニル｝−ピペリジン−１−カルボン酸エステル
JP2011526894A (ja) * 2008-07-03 2011-10-20 ユニバーシティ オブ バージニア パテント ファウンデーション アパデノソンの単位投薬量
US9415058B2 (en) 2008-07-03 2016-08-16 University Of Virginia Patent Foundation Unit dosage of Apadenoson
US9662406B2 (en) 2008-07-03 2017-05-30 University Of Virginia Patent Foundation Unit dosage of apadenoson

Also Published As

Publication number Publication date
DE60318192D1 (de) 2008-01-31
AU2003234716A1 (en) 2003-10-27
EP1496911A1 (en) 2005-01-19
DE60318192T2 (de) 2008-04-30
ATE381336T1 (de) 2008-01-15
WO2003086408A8 (en) 2005-01-13
US20090170803A1 (en) 2009-07-02
EP1496911B1 (en) 2007-12-19
WO2003086408A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
JP2006515829A (ja) 炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用
JP4514452B2 (ja) Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US10493071B2 (en) Use of pyrroloquinoline compounds to kill clinically latent microorganisms
US7396825B2 (en) Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
US8975417B2 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EP1341769B1 (en) Bacterial gyrase inhibitors and uses thereof
US7427606B2 (en) Method to reduce inflammatory response in transplanted tissue
US20100093691A1 (en) Topical formulations
CN105682655B (zh) 抗微生物化合物
JP2011509305A (ja) Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療
HU228937B1 (en) Compositions for treating inflammatory response
EP0873753A1 (en) Use of NK-1 receptor antagonists for the manufacture of a medicament in the treatment of symptoms of irritable bowel syndrome
US20090131405A1 (en) Imidazoazepinone compounds
KR20170131687A (ko) 박테리아 감염 예방 또는 치료용 헤테로사이클 화합물 및 이의 용도
WO2024092047A1 (en) Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis
AU774981B2 (en) Thiazolopyrimidines useful as TNFalpha inhibitors
TW201022254A (en) S1P lyase inhibitors for the treatment of cerebral malaria
CN119630393A (zh) 抗微生物化合物
HK1216251B (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100216